This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Breast International Group
Cancer and Leukemia Group B
National Cancer Institute (NCI)
NSABP Foundation Inc
NCIC Clinical Trials Group
North Central Cancer Treatment Group
Southwest Oncology Group
Information provided by (Responsible Party):
International Breast Cancer Study Group
ClinicalTrials.gov Identifier:
NCT00066690
First received: August 6, 2003
Last updated: July 29, 2016
Last verified: July 2016
Results First Received: July 14, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Estrogen Receptor Positive Breast Cancer
Progesterone Receptor Positive Tumor
Recurrent Breast Carcinoma
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Interventions: Drug: Exemestane
Other: Laboratory Biomarker Analysis
Procedure: Oophorectomy
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Tamoxifen
Drug: Triptorelin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
3066 patients were randomized between 17Dec03 and 27Jan11 at 426 centers in 25 countries.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Tamoxifen Tamoxifen 20mg orally daily for 5 years
T+OFS Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
E+OFS Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)

Participant Flow:   Overall Study
    Tamoxifen   T+OFS   E+OFS
STARTED   1021   1024   1021 
COMPLETED   423   502   457 
NOT COMPLETED   598   522   564 
Adverse Event                145                58                126 
Death                3                0                2 
Lack of Efficacy                114                110                76 
Lost to Follow-up                40                21                29 
Withdrawal by Subject                50                55                49 
Treatment Ongoing                246                278                282 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intention-to-treat population, excludes 19 patients who immediately withdrew consent.

Reporting Groups
  Description
Tamoxifen Tamoxifen 20mg orally daily for 5 years
T+OFS Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
E+OFS Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
Total Total of all reporting groups

Baseline Measures
   Tamoxifen   T+OFS   E+OFS   Total 
Overall Participants Analyzed 
[Units: Participants]
 1018   1015   1014   3047 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 43 
 (38 to 46) 
 43 
 (38 to 47) 
 43 
 (38 to 47) 
 43 
 (38 to 47) 
Gender [1] 
[Units: Percent of participants]
       
Female   100   100   100   300 
Male   0   0   0   0 
[1] Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.
Lymph-node status [1] 
[Units: Percent of participants]
       
Negative   65.03   65.22   66.17   196.42 
Positive   34.97   34.78   33.83   103.58 
[1] Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.
Tumor size [1] 
[Units: Percent of participants]
       
Unknown   2.65   2.46   2.07   7.18 
<=2 cm   66.40   64.63   66.86   197.89 
>2cm   30.94   32.91   31.07   94.92 
[1] Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.
Tumor grade [1] 
[Units: Percent of participants]
       
Unknown   2.36   2.36   2.17   6.89 
 27.01   26.11   24.36   77.48 
 48.33   50.64   53.65   152.62 
 22.30   20.89   19.82   63.01 
[1]

Tumor grade is the histologic grade according to the BRE method. The method involves assessment of tumor morphology, including tubule formation, nuclear pleomorphism and frequency of mitoses. Grades are recorded according to criteria as 1,2 or 3. Grade 3 is associated with poor prognosis.

Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.

HER2-status [1] 
[Units: Percent of participants]
       
Unknown   4.32   2.86   2.66   9.84 
Negative   84.18   85.42   84.52   254.12 
Positive   11.49   11.72   12.82   36.03 
[1] Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Disease-free Survival   [ Time Frame: 5-year estimates, reported at a median follow-up of 67 months. ]

2.  Secondary:   Breast Cancer-free Interval   [ Time Frame: 5-year estimates, reported at a median follow-up of 67 months. ]

3.  Secondary:   Distant Recurrence-free Interval   [ Time Frame: 5-year estimates, reported at a median follow-up of 67 months. ]

4.  Secondary:   Overall Survival   [ Time Frame: 5-year estimates ]
Results not yet reported.   Anticipated Reporting Date:   06/2017  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Rudolf Maibach, Executive Officer for International Trial Activities
Organization: IBCSG
phone: +41 31 389 91 96
e-mail: rudolf.maibach@ibcsg.org


Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: International Breast Cancer Study Group
ClinicalTrials.gov Identifier: NCT00066690     History of Changes
Obsolete Identifiers: NCT00917969, NCT02140190
Other Study ID Numbers: IBCSG 24-02
NCI-2009-01086 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CDR0000316456
BIG 2-02
2004-000166-13
IBCSG-24-02 ( Other Identifier: CTEP )
N02CM62212 ( U.S. NIH Grant/Contract )
U24CA075362 ( U.S. NIH Grant/Contract )
Study First Received: August 6, 2003
Results First Received: July 14, 2015
Last Updated: July 29, 2016